Table 1. The data of clinicopathologic features, TFE3 and cathepsin K IHC, PRCC-TFE3 FISH assay of PRCC-TFE3 renal cell carcinomas.

Case	Age(years)/Sex	Symptom	Operation	Tumor size(cm)	ACJJ stage	TFE3 IHC	cathepsin K IHC	PRCC-TFE3 dual-fusion FISH	Follow-up(months) and outcome
1	35/M	Symptomless	LRN	6	pT1bN0M0,Ⅰ	++	++	1R2F	52, Lung metastasis in 11 months, stable now.
2	22/F	Gross hematuria	LRN	5	pT1bN0M0,Ⅰ	+++	++	1G1R2F	40,Normal
3	25/F	Gross hematuria	LRN	3.5	pT1aNxM0,Ⅰ	++	+++	1G1R2F	15,Normal
4	45/F	Symptomless	ORN	12	pT3aN0M0,Ⅲ	+++	++	1G1R2F	32, Recur in 12 months
5	30/F	Symptomless	LRN	9.5	pT3aN0M0,Ⅲ	+++	+++	1G1R2F	22, Recur in 14 months
6	64/M	Symptomless	LNSS	3	pT1aN0M0,Ⅰ	++	+++	1R2F	5,Normal
7	26/M	Symptomless	ORN	3.7	pT1aN0M0,Ⅰ	+++	+++	1R2F	76,Normal

LRN: Laparoscopic radical nephrectomy; ORN: Open radical nephrectomy; LNSS: laparoscopic nephron-sparing surgery; IHC: immunohistochemistry; FISH: fluorescence in situ hybridization; TFE3, transcription factor E3.